Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Short Interest Update

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) was the target of a significant increase in short interest in the month of February. As of February 28th, there was short interest totalling 742,800 shares, an increase of 86.3% from the February 13th total of 398,700 shares. Based on an average trading volume of 817,700 shares, the short-interest ratio is presently 0.9 days. Currently, 1.5% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $25.00 price objective on shares of Milestone Pharmaceuticals in a research report on Friday, February 28th.

Milestone Pharmaceuticals Price Performance

Shares of Milestone Pharmaceuticals stock traded up $0.14 during trading hours on Friday, reaching $2.17. The stock had a trading volume of 2,438,222 shares, compared to its average volume of 388,516. The stock’s 50 day moving average is $2.02 and its 200 day moving average is $1.80. The firm has a market capitalization of $115.72 million, a PE ratio of -2.68 and a beta of 1.83. Milestone Pharmaceuticals has a twelve month low of $1.12 and a twelve month high of $2.75. The company has a current ratio of 15.40, a quick ratio of 15.40 and a debt-to-equity ratio of 2.18.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Jones Financial Companies Lllp raised its position in shares of Milestone Pharmaceuticals by 1,000.0% during the 4th quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company’s stock worth $26,000 after purchasing an additional 10,000 shares during the last quarter. National Bank of Canada FI raised its position in shares of Milestone Pharmaceuticals by 163.4% during the 4th quarter. National Bank of Canada FI now owns 18,700 shares of the company’s stock worth $44,000 after purchasing an additional 11,600 shares during the last quarter. Atria Investments Inc raised its position in shares of Milestone Pharmaceuticals by 44.4% during the 3rd quarter. Atria Investments Inc now owns 40,421 shares of the company’s stock worth $61,000 after purchasing an additional 12,430 shares during the last quarter. PVG Asset Management Corp acquired a new position in shares of Milestone Pharmaceuticals during the 3rd quarter worth about $46,000. Finally, Northern Trust Corp raised its position in shares of Milestone Pharmaceuticals by 112.6% during the 4th quarter. Northern Trust Corp now owns 58,108 shares of the company’s stock worth $137,000 after purchasing an additional 30,772 shares during the last quarter. Institutional investors and hedge funds own 86.18% of the company’s stock.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.